{
    "nctId": "NCT01782274",
    "briefTitle": "Proteome-based Immunotherapy of Brain Metastases From Breast Cancer",
    "officialTitle": "Proteome-based Personalized Immunotherapy of Brain Metastases From Breast Cancer",
    "overallStatus": "UNKNOWN",
    "conditions": "Neoplasm Metastasis",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2, PHASE3",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 60,
    "primaryOutcomeMeasure": "All cause mortality",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Morphologically confirmed breast cancer metastases to brain (in case of relapse and impossibility of biopsy, diagnosis based on radiological and other diagnostic methods)\n* Brain metastases of breast cancer refractor to the 1-st and following conventional chemotherapies and radiotherapy, in case their removal is not possible\n* Brain metastases of breast cancer relapses after no less than one course of conventional chemotherapy and radiotherapy in case their removal is not possible.\n* Availability of HLA partially compatible related donor\n* Life expectancy of no less than 3 months\n* Absence of severe decompensated organ dysfunction\n* Informed consent of the patient\n* Informed consent of the donor\n\nExclusion Criteria:\n\n* Failure to meet one of the inclusion criteria",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}